Skip to content

Anika Therapeutics ANIK Accounts Payable

Accounts Payable at other companies

Stryker logo
StrykerSYK
$1.59B+8.7%
Vericel logo
VericelVCEL
$19.01M+13.5%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$361.2M+19.9%
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$14.01M-39.5%
Bioventus logo
BioventusBVS
$24.05M+25.3%
Xtant Medical Holdings logo
Xtant Medical HoldingsXTNT
$5.49M-23.0%

Other financials

Income statement

See full
Revenue$29.6M+13.2%
Net income-$5.1M-3.8%

Balance sheet

See full
Cash & equivalents$41.0M-23.1%
Total debt$25.7M+1.2%
Total equity$133.9M-9.8%
Total assets$179.4M-5.9%

Cash flow

See full
Operating cash flow-$4.8M-3,628%
CapEx$1.4M-49.3%
Free cash flow-$6.3M-112%

Valuation

See full
Market cap$204.37M+31.6%
Enterprise value$189.09M+48.7%
P/S1.8×+0.1×

Profitability

See full
Net margin-9.8%-4.4pp
FCF margin0.9%

Returns & leverage

See full
Return on equity-8%-3.4pp
Debt / equity0.2×0.0×
Current ratio4.5×-1.3×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Anika Therapeutics's accounts payable?
Anika Therapeutics (ANIK) reported accounts payable of $6.34M in Q1 2026.
How has Anika Therapeutics's accounts payable changed year-over-year?
Anika Therapeutics's accounts payable increased by 20.1% year-over-year, from $5.28M to $6.34M.
What is the long-term trend for Anika Therapeutics's accounts payable?
Over 5 years (2020 to 2025), Anika Therapeutics's accounts payable has grown at a -7.6% compound annual growth rate (CAGR), from $8.98M to $6.04M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.